Resources & Guides

Five pipeline obesity drugs set side by side from their own trials: eloralintide, retatrutide, survodutide, mazdutide and CagriSema. Each number carries its trial, population, dose and estimand. We found no registered head-to-head trial of retatrutide with any of the four, so the matrix ranks nothing. Status checked November 4, 2026.

TRIUMPH-4 showed 28.7% weight loss at 68 weeks in December 2025. Seven more retatrutide trials report in 2026. Here is the full TRIUMPH program map, how to enroll, and what the timeline means for FDA approval.

A twice-weekly retatrutide split takes the same total weekly dose and divides it into two injections about 3 to 4 days apart. The 6-day half-life is what makes that spacing logical. Here is the pharmacokinetic reasoning, the practical mechanics, and the honest evidence picture.

Retatrutide activates three hormone receptors at once. Here is what it actually does inside the body: appetite suppression, metabolic shifts, blood sugar regulation, and fat loss, all grounded in published Phase 2 data.

People search "GLP-3 retatrutide" after hearing the nickname online. There is no GLP-3 receptor. Retatrutide is a triple agonist hitting GLP-1, GIP, and glucagon. Here is where the name came from and what it means.

Retatrutide has a small published trial record and no marketed population, so its hair-loss evidence is thin by construction. This guide separates what was reported from what is inference.

Patients searching for a retatrutide compounding pharmacy expect a licensed pharmacist with a white coat. The federal reality is sharper: neither 503A pharmacies nor 503B outsourcing facilities can legally produce retatrutide, because both pathways require the active ingredient to sit on an FDA-evaluated list, and retatrutide does not. This guide explains both frameworks in plain English, then traces what people actually receive when they buy from a site that calls itself a compounding pharmacy.